- Home
- SENEA vs TRDA Comparison
SENEA vs TRDA Comparison
Compare SENEA & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- TRDA
- Stock Information
- Founded
- SENEA 1949
- TRDA 2016
- Country
- SENEA United States
- TRDA United States
- Employees
- SENEA N/A
- TRDA N/A
- Industry
- SENEA Packaged Foods
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- TRDA Health Care
- Exchange
- SENEA Nasdaq
- TRDA Nasdaq
- Market Cap
- SENEA 595.0M
- TRDA 502.9M
- IPO Year
- SENEA N/A
- TRDA 2021
- Fundamental
- Price
- SENEA $88.49
- TRDA $9.03
- Analyst Decision
- SENEA
- TRDA Strong Buy
- Analyst Count
- SENEA 0
- TRDA 3
- Target Price
- SENEA N/A
- TRDA $25.67
- AVG Volume (30 Days)
- SENEA 32.4K
- TRDA 110.4K
- Earning Date
- SENEA 02-06-2025
- TRDA 05-06-2025
- Dividend Yield
- SENEA N/A
- TRDA N/A
- EPS Growth
- SENEA 25.61
- TRDA N/A
- EPS
- SENEA 5.45
- TRDA 1.68
- Revenue
- SENEA $1,541,031,000.00
- TRDA $210,782,000.00
- Revenue This Year
- SENEA N/A
- TRDA N/A
- Revenue Next Year
- SENEA N/A
- TRDA N/A
- P/E Ratio
- SENEA $16.58
- TRDA $5.69
- Revenue Growth
- SENEA 4.00
- TRDA 63.38
- 52 Week Low
- SENEA $51.79
- TRDA $9.51
- 52 Week High
- SENEA $90.35
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- SENEA 60.41
- TRDA 26.45
- Support Level
- SENEA $84.41
- TRDA $9.75
- Resistance Level
- SENEA $88.91
- TRDA $10.87
- Average True Range (ATR)
- SENEA 2.37
- TRDA 0.53
- MACD
- SENEA -0.05
- TRDA -0.05
- Stochastic Oscillator
- SENEA 70.31
- TRDA 6.97
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.